PortalPublikationenComparison of outcomes for HLA-matched sibling and haplo-ide...

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

Standard

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. / Raj, Kavita; Eikema, Dirk-Jan; Sheth, Vipul; Koster, Linda; de Wreede, Liesbeth C; Blaise, Didier; Di Grazia, Carmela; Koc, Yener; Potter, Victoria; Chevallier, Patrice; Lopez-Corral, Lucia; Wu, Depei; Mielke, Stephan; Maertens, Johan; Meijer, Ellen; Huynh, Anne; Passweg, Jakob; Luft, Thomas; Pérez-Simón, Jose Antonio; Ciceri, Fabio; Piekarska, Agnieszka; Hayri Ozsan, G; Kröger, Nicolaus; Robin, Marie; Yakoub-Agha, Ibrahim.

in: BLOOD CANCER J, Jahrgang 12, Nr. 9, 28.09.2022, S. 140.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Raj, K, Eikema, D-J, Sheth, V, Koster, L, de Wreede, LC, Blaise, D, Di Grazia, C, Koc, Y, Potter, V, Chevallier, P, Lopez-Corral, L, Wu, D, Mielke, S, Maertens, J, Meijer, E, Huynh, A, Passweg, J, Luft, T, Pérez-Simón, JA, Ciceri, F, Piekarska, A, Hayri Ozsan, G, Kröger, N, Robin, M & Yakoub-Agha, I 2022, 'Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT', BLOOD CANCER J, Jg. 12, Nr. 9, S. 140. https://doi.org/10.1038/s41408-022-00729-y

APA

Raj, K., Eikema, D-J., Sheth, V., Koster, L., de Wreede, L. C., Blaise, D., Di Grazia, C., Koc, Y., Potter, V., Chevallier, P., Lopez-Corral, L., Wu, D., Mielke, S., Maertens, J., Meijer, E., Huynh, A., Passweg, J., Luft, T., Pérez-Simón, J. A., ... Yakoub-Agha, I. (2022). Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. BLOOD CANCER J, 12(9), 140. https://doi.org/10.1038/s41408-022-00729-y

Vancouver

Raj K, Eikema D-J, Sheth V, Koster L, de Wreede LC, Blaise D et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. BLOOD CANCER J. 2022 Sep 28;12(9):140. https://doi.org/10.1038/s41408-022-00729-y

Bibtex

@article{0bdf178b88fd4d8c94505e7d260235f8,
title = "Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT",
abstract = "Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p ≤ 0.001, and 51% vs 47%, p = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% (p = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant [HR 2.59 (1.5-4.48) p < 0.001] and was also higher at 2 years being 30% for HD and 20% for MSD, p ≤ 0.001. The incidence of acute GVHD grade II-IV and III-IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD (p < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months [HR 1.93(1.24-3.0)], and HR [3.5(1.5-8.1)]. The median age of HD 37 (IQR 30-47) years was significantly lower than sibling donors 56 (IQR 49-62 years) p < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it's use when no better donor is available.",
keywords = "Adult, Cyclophosphamide/therapeutic use, Graft vs Host Disease/epidemiology, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Myelodysplastic Syndromes/drug therapy, Neoplasms/drug therapy, Recurrence, Retrospective Studies, Siblings, Transplantation Conditioning, Unrelated Donors",
author = "Kavita Raj and Dirk-Jan Eikema and Vipul Sheth and Linda Koster and {de Wreede}, {Liesbeth C} and Didier Blaise and {Di Grazia}, Carmela and Yener Koc and Victoria Potter and Patrice Chevallier and Lucia Lopez-Corral and Depei Wu and Stephan Mielke and Johan Maertens and Ellen Meijer and Anne Huynh and Jakob Passweg and Thomas Luft and P{\'e}rez-Sim{\'o}n, {Jose Antonio} and Fabio Ciceri and Agnieszka Piekarska and {Hayri Ozsan}, G and Nicolaus Kr{\"o}ger and Marie Robin and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = sep,
day = "28",
doi = "10.1038/s41408-022-00729-y",
language = "English",
volume = "12",
pages = "140",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

AU - Raj, Kavita

AU - Eikema, Dirk-Jan

AU - Sheth, Vipul

AU - Koster, Linda

AU - de Wreede, Liesbeth C

AU - Blaise, Didier

AU - Di Grazia, Carmela

AU - Koc, Yener

AU - Potter, Victoria

AU - Chevallier, Patrice

AU - Lopez-Corral, Lucia

AU - Wu, Depei

AU - Mielke, Stephan

AU - Maertens, Johan

AU - Meijer, Ellen

AU - Huynh, Anne

AU - Passweg, Jakob

AU - Luft, Thomas

AU - Pérez-Simón, Jose Antonio

AU - Ciceri, Fabio

AU - Piekarska, Agnieszka

AU - Hayri Ozsan, G

AU - Kröger, Nicolaus

AU - Robin, Marie

AU - Yakoub-Agha, Ibrahim

N1 - © 2022. The Author(s).

PY - 2022/9/28

Y1 - 2022/9/28

N2 - Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p ≤ 0.001, and 51% vs 47%, p = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% (p = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant [HR 2.59 (1.5-4.48) p < 0.001] and was also higher at 2 years being 30% for HD and 20% for MSD, p ≤ 0.001. The incidence of acute GVHD grade II-IV and III-IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD (p < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months [HR 1.93(1.24-3.0)], and HR [3.5(1.5-8.1)]. The median age of HD 37 (IQR 30-47) years was significantly lower than sibling donors 56 (IQR 49-62 years) p < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it's use when no better donor is available.

AB - Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p ≤ 0.001, and 51% vs 47%, p = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% (p = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant [HR 2.59 (1.5-4.48) p < 0.001] and was also higher at 2 years being 30% for HD and 20% for MSD, p ≤ 0.001. The incidence of acute GVHD grade II-IV and III-IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD (p < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months [HR 1.93(1.24-3.0)], and HR [3.5(1.5-8.1)]. The median age of HD 37 (IQR 30-47) years was significantly lower than sibling donors 56 (IQR 49-62 years) p < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it's use when no better donor is available.

KW - Adult

KW - Cyclophosphamide/therapeutic use

KW - Graft vs Host Disease/epidemiology

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Middle Aged

KW - Myelodysplastic Syndromes/drug therapy

KW - Neoplasms/drug therapy

KW - Recurrence

KW - Retrospective Studies

KW - Siblings

KW - Transplantation Conditioning

KW - Unrelated Donors

U2 - 10.1038/s41408-022-00729-y

DO - 10.1038/s41408-022-00729-y

M3 - SCORING: Journal article

C2 - 36167679

VL - 12

SP - 140

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 9

ER -